Assessment of rates of acute adverse reactions to gadobenate dimeglumine: Review of more than 130,000 administrations in 7.5 years

American Journal of Roentgenology

Volumn 204, Issue 4, 2015, Pages 703-706

  Fakhran, Saeed ^a   Alhilali, Lea ^a   Kale, Hrishikesh ^a   Kanal, Emanuel ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Gadolinium; IV contrast administration; MRI safety

Indexed keywords

GADOBENATE DIMEGLUMINE; CONTRAST MEDIUM; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ARTICLE; COMMUNITY HOSPITAL; DIZZINESS; DRUG SAFETY; DYSPNEA; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSIVE CRISIS; INCIDENCE; NAUSEA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR PRURITUS; PERIORAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN TINGLING; SNEEZING; THORAX PAIN; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; ANALOGS AND DERIVATIVES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH CARE QUALITY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

CONTRAST MEDIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PENNSYLVANIA; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 84929629284     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.13430     Document Type: Article

References (34)

1. Bleicher A, Kanal E. Assessment of adverse reactions rates to a newly approved MRI contrast agent: review of 23, 553 administrations of gadobenate dimeglumine. AJR 2008; 191:[web]W307-W311
2. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR 2007; 189:1533-1538
3. Prince M, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR 2011; 196:[web]W138-W143
4. Matsumura T, Hayakawa M, Shimada F, et al. Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci 2013; 12:297-304
5. Raisch DW, Garg V, Arabyat R, et al. Anaphy-laxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf 2014; 13:15-23
6. Davenport MS, Dillman JR, Cohan RH, et al. Effect of abrupt substitution of gadobenate dimeglu-mine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 2013; 266:773-782
7. Knopp MV, Balzer T, Esser M, et al. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations over 15 years of clinical use. Invest Radiol 2006; 41:491-499
8. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra-and interindividual comparison studies with gadopentetate dimeglu-mine. J Magn Reson Imaging 2006; 24:1378-1385
9. U.S. Food and Drug Administration, Center for Bi-ologics Evaluation and Research website. Guideline for industry: clinical safety data management-defnitions and standards for expedited reporting, 1995. www.fda.gov/downloads/drugs/guidance complianceregulatoryinformation/guidances/ucm 073087.pdf. Accessed December 18, 2014
10. U.S. Food and Drug Administration, Center for Bi-ologics Evaluation and Research website. ICH harmonised tripartite guideline draft: postapproval safety data management-defnitions and standards for expedited reporting, 2003. www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm073106.pdf. Accessed December 18, 2014
11. U.S. Food and Drug Administration, Center for Bi-ologics Evaluation and Research website. Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products-content and format, 2006. www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm075057.pdf. Accessed D ecember 18, 2014
12. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the defnition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584-591
13. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the defnition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391-397
14. U.S. Food and Drug Administration website. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI). www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm 053112.htm. Published June 8, 2006. Updated December 2010. Accessed August 30, 2012
15. American College of Radiology. Manual on contrast media, 7th ed. Reston, VA: American College of Radiology, 2011
16. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fbrosis. Radiology 2007; 242:647-649
17. Marin D, Iannaccone R, Laghi A, et al. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine-and feru-carbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2007; 25:775-782
18. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007; 106:557-566
19. Runge VM, Biswas J, Wintersperger BJ, et al. The effcacy of gadobenate dimeglumine (Gd-BOP-TA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol 2006; 41:244-248
20. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and post marketing surveillance. Invest Radiol 2006; 41:500-509
21. Herborn CU, Jager-Booth I, Lodemann K P, et al. Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance). Rofo 2009; 181:652-657
22. Schneider G, Schurholz H, Kirchin MA, et al. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglu-mine (MultiHance) in children. Pediatr Radiol 2013; 43:202-211
23. Kirchin MA, Pirovano G, Venetianer C, et al. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001; 14:281-294
24. Bailar JC 3rd. The promise and problems of meta-analysis. N Engl J Med 1997; 337:559-561
25. LeLorier J, Gregoire G. Comparing results from me-ta-analyses vs. large trials. JAMA 1998; 280: 518-519
26. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542
27. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14:426-435
28. Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32, 659 injections. AJR 2010; 194:430-434
29. Morgan DE, Spann JS, Lockhart ME, Winning-ham B, Bolus DN. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28, 078 patients. Radiology 2011; 259:109-116
30. Hieronim DE, Kanal E, Swanson DP. Dosage of gadoter idol and adverse reactions relative to gadopen-tetate. Am J Health Syst Pharm 1995; 52:2556-2559
31. Weber JC. Epidemiology of adverse reactions to nonsteroidal anti-infammatory drugs. In: Rains-ford KD, Velo GP, eds. Advances in infammation research, vol. 6. New York, NY: Raven, 1984:1-7
32. Hartnell NR, Wilson J P, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003; 37:1387-1391
33. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24:233-237
34. Lalli AF. Contrast media reactions: data analysis and hypothesis. Radiology 1980; 134:1-12